InnoCare Published P-II Study Results of Orelabrutinib in P-II Study for Cancers in American Journal of Hematology
Shots:
- The P-II study evaluates orelabrutinib (BTK inhibitor) in 80 patients which showed IRC-assessed ORR (92.5%) & CR (21.3%). Based on the investigator evaluation, the ORR & CR were 93.8% & 26.3% respectively, m-PFS (not reached) and the 30mos. PFS rate (70.9%) & OS (81.3%), substantial response in patients with high prognostic risks were reported
- In patients with del(17p) or TP53 mutation/del(11q)/unmutated IGHV, ORR (100%/94.7%/93.9%), respectively, the median time to first response was 1.9mos., CR/CRi rate & ORR increased from 3.8% to 21.3% & 88.8% to 92.5% at a median follow-up of 8.7mos. & 32.3mos.
- The therapy showed a well-tolerated safety profile & is being studied in the P-II studies for MS, SLE, ITP, and NMOSD in China
Ref: Businesswire | Image: InnoCare
Related Post:- InnoCare Reports First Patient Dosing of Orelabrutinib in P-II Clinical Trial for the Treatment of ITP
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
